Anteris Technologies Achieves Breakthrough in Triple Valve Replacement Using DurAVR™

Anteris Technologies Achieves Breakthrough in Triple Valve Replacement Using DurAVR™

Key Takeaways (TLDR)

• Anteris Technologies achieved a breakthrough in triple valve replacement using DurAVR™, providing a competitive edge in complex cases.

• The DurAVR™ transcatheter aortic valve replacement (TAVR) system is a single-piece native-shaped tissue valve, designed for ease of use and effectiveness.

• The innovative DurAVR™ system significantly improves the patient's condition, offering hope and better outcomes in challenging medical cases.

• The procedure at Karolinska University Hospital in Stockholm, Sweden, showcases the incredible potential and impact of biomimetic technology in healthcare.

Why it Matters

The successful 'valve-in-valve-in-valve' procedure using the DurAVR™ system marks a significant advancement in the field of transcatheter aortic valve replacement. This breakthrough has the potential to provide valuable alternative options for patients with complex cases and high surgical risk, ultimately improving their quality of life and treatment outcomes.

Summary

Anteris Technologies CEO Wayne Paterson discusses the successful 'valve-in-valve-in-valve' procedure using the DurAVR™ transcatheter aortic valve replacement system. The procedure, performed at Karolinska University Hospital in Sweden, was a breakthrough in triple valve replacement, highlighting the effectiveness of the DurAVR™ system even in complex cases.

This news story relied on a press release distributed by News Direct. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Anteris Technologies Achieves Breakthrough in Triple Valve Replacement Using DurAVR™.